budesonide NDC 16714-829

NDC codes

FDA NDC Directory

Product NDC (as listed)16714-829Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16714-0829Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16714-829-01	16714082901	100 CAPSULE, COATED PELLETS in 1 BOTTLE (16714-829-01)Marketed from Jun 25, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): budesonide
Generic name (nonproprietary): budesonide
Active ingredients: Budesonide — 3 mg/1
Dosage form: Capsule, Coated pellets
Route: Oral
Labeler: Northstar Rx LLC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206134
Marketing start: Jun 25, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 16714-829_1780fdb2-9492-4cec-840e-923f19561188SPL ID 1780fdb2-9492-4cec-840e-923f19561188SPL set ID a37866df-df07-4f71-8591-98c2804c4794RxCUI 1244214UNII Q3OKS62Q6XUPC 0316714829012
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N416714082901 followed by a unit qualifier and the quantity

Package 16714-0829-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 18, 2025.

Indications (excerpt from the label)

Budesonide delayed-release capsules are corticosteroid indicated for: Treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, in patients 8 years and older. ( 1.1 ) Maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults. ( 1.2 ) 1.1 Treatment of Mild to Moderate Active Crohn’s Disease Budesonide delayed-release capsules are indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in patients 8 years of age and older. 1.2 Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease Budesoni…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206134

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206134
Product	Strength	Form · route	Labeler	Product NDC
budesonide	Budesonide 3 mg/1	Capsule, Coated pelletsOral	Zydus Lifesciences Limited	70771-1075
Budesonide	Budesonide 3 mg/1	Capsule, Coated pelletsOral	American Health Packaging	60687-596
budesonide	Budesonide 3 mg/1	Capsule, Coated pelletsOral	Zydus Pharmaceuticals USA Inc.	68382-720
budesonide	Budesonide 3 mg/1	Capsule, Coated pelletsOral	Major Pharmaceuticals	0904-7313
budesonide	Budesonide 3 mg/1	Capsule, Coated pelletsOral	REMEDYREPACK INC.	70518-4613